Description:
E5103 24-months Post-Registration Cardiac Function Assessment Form NCT00433511 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=8C9D1499-1276-D754-E040-BB89AD43467F
Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=8C9D1499-1276-D754-E040-BB89AD43467FKeywords:
Versions (3)
- 8/26/12 8/26/12 -
- 1/9/15 1/9/15 - Martin Dugas
- 6/16/15 6/16/15 -
Uploaded on:
June 16, 2015
DOI:
To request one please log in.License :
Creative Commons BY-NC 3.0 LegacyModel comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
INSTRUCTIONS: Use this form ONLY when submitting results from the 24 months post-registration cardiac assessment. For any cardiac data obtained prior to the 24-month timepoint, please use the E5103 Cardiac Toxicity Form
- StudyEvent: E5103 24-months Post-Registration Cardiac Function Assessment Form